castration-resistant prostate cancer

Source: Pixabay.com

The FDA Have Approved Xtandi® as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Post author:Anna Hewitt
Post published:July 23, 2018
Post category:Cancer

A drug to treat prostate cancer has been approved by the US Food and Drug Administration. The drug, Xtandi ® (enzalutamide), had previously been approved for castration-resistant prostate cancer (CRPC)…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More